• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
COVID-19 Management

RCT Results: Convalescent Plasma for the Treatment of COVID-19

image_pdfFavoriteLoadingFavorite

PURPOSE:

  • Li et al. (JAMA, 2020) assessed the efficacy of convalescent plasma therapy for the treatment of patients with severe or life-threatening COVID-19

METHODS:

  • Open-label, multicenter, randomized clinical trial (February 14 to April 1, 2020)
    • 7 centers in Wuhan, China
  • Participants
    • Laboratory-confirmed COVID-19
      • Severe: Respiratory distress and/or hypoxemia or
      • Life-threatening: Shock | Organ failure | Mechanical ventilation
  • Randomization (1:1)
    • Intervention group: Standard treatment and convalescent plasma transfusion
    • Control: Standard treatment alone
  • Convalescent plasma transfusion protocol
    • Dose: 4 to 13 mL/kg | ABO type compatible
    • Transfused at approximately 10 mL for the first 15 minutes and then increased to approximately 100 mL/hour
  • Primary outcome
    • Clinical improvement within 28 days
    • Determined using a 6 point disease severity scale | Improvement defined as a 2 point reduction
  • Secondary outcomes included
    • 28-day mortality | Duration of hospitalization | Time from admission to discharge and 28-day discharge rates | Conversion of nasopharyngeal viral PCR results (positive to negative)
  • Statistical analysis
    • 2-sided significance level of α = .05 | 80% power
    • Would require 100 in each group to detect an 8 day change  

RESULTS:

  • 103 patients randomized
    • Median age: 70 years | Male 58.3%
    • Median time from symptom onset to randomization: 30 days

Primary Outcome: Overall Clinical Improvement at 28 days

  • Overall
    • Clinical improvement was greater in the convalescent plasma group (51.9%) vs control group (43.1%) but was not statistically significant
    • Hazard ratio (HR):  1.40 (95% CI, 0.79 to 2.49; P = .26)
  • In the severe disease subgroup
    • Clinical improvement was greater in the convalescent plasma group (91.3%) vs control group (68.2%) and this difference was statistically significant
    • HR: 2.15 (95% CI, 1.07 to 4.32; P = .03)
  • In the life-threatening disease subgroup
    • Clinical improvement was decreased (20.7%) vs the control group (24.1%) but this difference was not statistically significant
    • HR: 0.88 (95% CI, 0.30 to 2.63; P = .83)
  • No differences were found for the following
    • 28-day mortality
    • Time from randomization to discharge
  • Conversion rates from a positive to a negative SARS-CoV-2 test (at 72 hours) was higher in the convalescent plasma group (87.2%) vs control group (37.5%) 
    • Odds ratio (OR): 11.39 (95% CI, 3.91 to 33.18; P < .001)
    • Likewise, conversion rates were higher in the convalescent plasma group at 24 and 48 hours
  • 2 adverse events (both patients improved with supportive care)
    • 1 patient developed chills and rash (nonsevere allergic transfusion)
    • 1 patient had severe transfusion-associated dyspnea

CONCLUSION:

  • While overall, convalescent plasma therapy did not improve clinical course of patients with severe or life-threatening COVID-19, there may be benefit in the severe subset of patients
  • The association with higher conversion rates (from positive to negative test results) would support the hypothesis that convalescent plasma does have antiviral activity in these patients
  • Authors acknowledge study limitations
    • Study was stopped early due to COVID-19 containment in Wuhan and insufficient cases to continue recruitment and therefore may have been underpowered  
    • Patients received therapy approximately a month (median value) after symptom onset and therefore unclear if earlier intervention would result in greater benefit

Learn More – Primary Sources:

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19

Get COVID-19 Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19 Management Posts
Next >

Related ObG Topics:

More Evidence Suggesting Convalescent Plasma Therapy May Be Effective in Patients with Severe COVID-19
Use of Convalescent Plasma in Critically Ill COVID-19 Patients: Results from a Preliminary Study
COVID-19 Guidance: Key Highlights for Healthcare Professionals

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site